New York, New York–(Newsfile Corp. – January 23, 2025) – WHY: The Rosen Law Firm, a global investor rights law firm, reminds purchasers of Pacira BioSciences, Inc.’s securities. (NASDAQ: PCRX) between August 2, 2023 and August 8, 2024, both dates inclusive (the “Class Period”), in material March 14, 2025 leads the plaintiff’s deadline.

WHATEVER: If you purchased Pacira securities during the Class, you may be entitled to compensation free of any out-of-pocket fees or expenses through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Pacira class action, go to https://rosenlegal.com/submit-form/?case_id=33570 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for class action information. A class action lawsuit has been filed. If you want to serve as the lead plaintiff, you must move the Court no later than March 14, 2025. The lead plaintiff is a representative party acting on behalf of other class members in the conduct of litigation.

WHY ROSEN LAW: We encourage investors to select qualified advisors with a track record of success in leadership roles. Often, the companies issuing the notices don’t have the same experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen who refer clients or partners to the law firms that actually litigate the cases. Be wise in choosing advice. The Rosen Law Firm represents investors worldwide, concentrating its practice in securities class actions and shareholder derivative litigation. The Rosen Law Firm achieved the largest securities class action settlement against a Chinese Company at that time. The Rosen Law Firm is ranked No. 1 in the ISS Securities Class action (WA:) Services for the number of securities class action settlements in 2017. The company has been ranked in the top 4 every year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the company earned over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

CASE DETAILS: According to the lawsuit, the statements made during the Class Period were false and/or misleading because the defendants created the false impression that Pacira had adequate patent protection for Exparel and, thus, the ability to expand marketing. , production, and sales of Exparel, which Pacira stated is critical to its future growth and profitability. In fact, Pacira’s optimistic claims about Exparel’s patent protections are extremely weak. In fact, Pacira found that the ‘495 patent was not as protective as the defendants had publicly stated because on June 6, 2023 the New Jersey District Court issued a decision in favor of eVenus regarding the establishment of claims in another lawsuit filed by Pacira in a failed defense attempt. Exparel. Yet the defendants continued to make public statements attesting to their belief in the ‘495 patent and the protection it applied to Exparel. When the true details entered the market, the lawsuit claimed that investors suffered damages.

To join the Pacira class action, go to https://rosenlegal.com/submit-form/?case_id=33570 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for class action information.

No Class Verified. Until a class is certified, you will not be represented by counsel unless you hold one. You can choose the advice you want. You can also stay out of class and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent on serving as the lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook (NASDAQ:): https :// /www.facebook.com/rosenlawfirm.

Attorney Advertising. The first results do not guarantee a similar result.

—————————-

To view the original version of this press release, please visit https://www.newsfilecorp.com/release/238246